Pharmaceuticals Search Engine [selected websites]

Showing posts with label Embla Systems. Show all posts
Showing posts with label Embla Systems. Show all posts

Monday, September 19, 2011

Natus Acquires Embla, Leading Sleep Diagnostic Company

Sep 16, 2011 - Acquisition expected to add $0.08 to 2012 non-GAAP Earnings Per Share -- Natus Medical Incorporated (Nasdaq:BABY) announced that it has acquired Embla Systems LLC, a leader in the development, manufacturing, and sales of devices used in the diagnosis of sleep apnea. Embla is the largest company in the world focused solely on sleep diagnostics (Polysomnography or PSG and Home Sleep Testing). The company offers a wide spectrum of innovative sleep diagnostic solutions including Embletta home sleep testing devices and three leading PSG platforms: Sandman, REMbrandt, and RemLogic, and Enterprise Sleep Business Management Systems. This breadth of product offerings provides a unique set of tools to help optimize the efficiency of sleep labs.

Natus Medical

Natus acquired all outstanding shares of Embla capital stock for $16.1 million in cash, exclusive of direct costs of the acquisition. Embla reported revenue of approximately $30 million for its fiscal year ended December 31, 2010.

Embla Systems

Natus expects the acquisition will be accretive to earnings in 2012, adding $0.08 to non-GAAP earnings per share for the year. The non-GAAP results will exclude amortization of acquired intangible assets and potential restructuring and other one-time charges related to the acquisition... Natus Medical's Press Release -

Thursday, October 29, 2009

Covidien : Sale of Sleep Diagnostics Product Line

Sep. 21, 2009-- Covidien, a leading global provider of healthcare products, announced that it had completed the previously announced sale of its Sleep Diagnostics assets to Embla Systems. Financial terms of the transaction were not disclosed.

The sale of the Sleep Diagnostics product line, which includes several products sold under the Sandman™ brand, was made following a thorough review and evaluation of a number of strategic alternatives. The decision is consistent with Covidien’s strategy to streamline its portfolio and reallocate resources to its faster-growing, higher-margin businesses, where the Company has or can develop a global competitive advantage... Covidien's Press Release -

Thursday, December 27, 2007

Embla Systems, to develop Cardio-Pulmonary Coupling Technology

Dec. 13 , 2007- Embla Systems, a leader in the field ofsleep diagnostic software and equipment announced today the signing of an exclusive agreement with the Beth Israel Deaconess Medical Center (BIDMC) for the distribution of the Cardio Pulmonary Coupling (CPC) technology developed by Drs. Robert Thomas, Ary Goldberger, C-K. Peng, and Mr. Joseph Mietus... The CPC technology will give physicians the "Sleep Health" of a patient and to evaluate if the patient has Obstructive, Central or Complex Sleep Apnea ... [PDF] Embla's Press Release -